When CML Therapy Shifts: Collaborative Approaches to Treatment Changes

Clinical guidelines aimed at both clinicians and patients seek to educate and include both parties in clinical decision-making processes.

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Results from the FELIX study showed that obe-cel induces high rates of MRD-negative remission in relapsed/refractory B-ALL, leading to improved EFS and OS.

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Obe-cel shows efficacy in R/R B-ALL, especially in those with a favorable CAR-HT risk profile, according to data from the phase 1/2 FELIX study.

A total of 3 patients with AML treated with the lowest dose of tuspetinib at 40 mg completed the first cycle of treatment with no dose-limiting toxicities.